The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP). Methods: A Markov model was developed to estimate the cost effectiveness of the three TPO-RAs in adults with insufficient response to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nichola Cooper, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James, Mondher Toumi, Anna Tytuła, Carly Rich, Daniel Eriksson
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Journal of Market Access & Health Policy
Subjects:	avatrombopag cost-effectiveness eltrombopag immune thrombocytopenia incremental cost-effectiveness ratio romiplostim
Online Access:	https://www.mdpi.com/2001-6689/13/2/11
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)

Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis
by: Xiaofang Zhang, et al.
Published: (2025-06-01)

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
by: M. V. Maevskaya, et al.
Published: (2024-08-01)

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy
by: VA Shuvaev, et al.
Published: (2017-10-01)

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice
by: II Zotova, et al.
Published: (2017-01-01)

Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01)

Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments
by: Andrea Aiello, et al.
Published: (2023-12-01)

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia
by: Paschalis Evangelidis, et al.
Published: (2025-01-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
by: María Henar García Lagunar, et al.
Published: (2015-02-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01)

Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
by: Vikas Talreja, et al.

The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia
by: Nan Wang, et al.
Published: (2025-08-01)

Investigation of the <i>ABCB1</i> Gene Polymorphism and Food Effects on the Avatrombopag Pharmacokinetics in Chinese Individuals: A Population Pharmacokinetic/Pharmacodynamic Analysis
by: Xin Liu, et al.
Published: (2025-06-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Initial Data on Clinical Use of Generic Romiplostim for Second-Line and Subsequent Therapy of Immune Thrombocytopenia in India
by: Suvir Singh, et al.
Published: (2021-01-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for avatrombopag
by: Zhong Xue, et al.
Published: (2024-11-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Acute myocardial infarction induced by avatrombopag: a case report
by: Gou Junqi, et al.
Published: (2025-08-01)

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01)

PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA
by: Roberto Stasi, et al.
Published: (2009-11-01)

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag
by: Antonella Sau, et al.
Published: (2025-04-01)

Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease
by: Faisal Alsayegh, et al.
Published: (2025-01-01)

Urogenital haemorrhage secondary to Babesia gibsoni induced immune thrombocytopenia and its management with combination of romiplostim and prednisolone in a dog
by: Nadima Khan, et al.
Published: (2025-06-01)

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01)

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Cost‐Utility Analysis of Low‐Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack
by: Fei Yuan, et al.
Published: (2024-11-01)

Analysis of the efficacy of avatrombopag for the delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation for aplastic anemia
by: Xinhe Zhang, et al.
Published: (2025-08-01)

PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE
by: Simone Baldini, et al.
Published: (2012-06-01)

Cost-effectiveness of physical activity-oriented interventions for improving mental health: a systematic review
by: Noara Alhusseini, et al.
Published: (2025-05-01)

Development and Validation of Eltrombopag Determination in Human Plasma Blood by HPLC-MS Method
by: А. М. AL-Dhuraibi, et al.
Published: (2022-11-01)

Cost-effectiveness of chemotherapy in advanced and recurrent endometrial cancer
by: Katsuaki Inami
Published: (2025-06-01)

Quality-adjusted Life Years and Costs of Mechanical Thrombectomy for Very Elderly Patients with Acute Ischaemic Stroke
by: Takeshi INABA, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease
by: Yueyang Huang, et al.
Published: (2025-05-01)

Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study
by: Xijuan Lin, et al.
Published: (2025-12-01)